CARDIOVASCULAR RISK ASSOCIATED WITH ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER

DEEPTHI C DENNY; YOGAVADULA SS; VIJAY R; MOHAMED FARDAN; DIVYA SARA IYPE; ABI MAHESHWARAN K

doi:10.22159/ajpcr.2021.v14i8.41946

Authors

DEEPTHI C DENNY Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India.
YOGAVADULA SS Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India.
VIJAY R Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India.
MOHAMED FARDAN Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India.
DIVYA SARA IYPE Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India.
ABI MAHESHWARAN K Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i8.41946

Keywords:

Prostate cancer, Androgen deprivation therapy, Testosterone, Cardiovascular complications, Gonadotropin-releasing hormone agonist

Abstract

Cancer is a lethal disease that is the second leading cause of mortality in the world. According to statistics, prostate cancer is one of the most common types among men. Male hormone androgens, particularly testosterone, are required for normal growth and functioning of the prostate. In prostate cancer, activation of the androgen receptor promotes the growth of cancer cells. The goal of hormonal therapy or androgen deprivation therapy (ADT) is to reduce levels of such male hormones in the body or prevent them from stimulating cancer cells. There are many issues that have to be considered before initiation of hormonal therapy which are necessary to be aware of for its prevention and the management in routine clinical practices. In this review article, we emphasis on cardiovascular complications following ADT and certain treatment measures.

Downloads

Download data is not yet available.

References

Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol 2021;2021:1-20.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.

Rani P, Singh K, Arjuna A, Devi S. Detection of prostate cancer: A review. Asian J Pharm Clin Res 2018;11:25-1.

Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92.

Hariharan K, Padmanabha V. Demography and disease characteristics of prostate cancer in India. Indian J Urol 2016;32:103.

SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute; 2016. Available from: https://www.seer.cancer.gov/ csr/1975_2015; Available from: https://www.seer.cancer.gov/explorer/ application.php. [Last accessed on 2019 Feb 04].

Chen FZ, Zhao XK. Prostate cancer: Current treatment and prevention strategies. Iran Red Crescent Med J 2013;15:279.

Gasnier A, Parvizi N. Updates on the diagnosis and treatment of prostate cancer. Br J Radiol 2017;90:20170180.

Pirtskhalaishvili G, Hrebinko RL, Nelson JB. The treatment of prostate cancer. An overview of current options. Cancer Pract 2001;9:295-306.

Nevedomskaya E, Baumgart SJ, Haendler B. Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci 2018;19:1359.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason M. Neo‐adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;4:CD006019.

Smith MR. Androgen deprivation therapy for prostate cancer: New concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007;14:247.

DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin YD, Ellingrod V. Pharmacotherapy: A Pathophysiologic Approach. 11th ed., Ch. 148. New York: McGraw-Hill Education; 2020. p. 6604-49.

Lester JF, Mason MD. Cardiovascular effects of hormone therapy for prostate cancer. Drug Healthc Patient Saf 2015;7:129.

Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67:825-36.

Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.

US Food and Drug Administration. FDA Drug Safety Communication: Update to Ongoing Safety Review of GnRH Agonists and Notification to Manufacturers of GnRH Agonists to Add New Safety Information to Labeling Regarding Increased Risk of Diabetes and Certain Cardiovascular Diseases. Silver Spring, MD: US Food and Drug Administration; 2010.

Nassar GN, Leslie SW. Physiology, Testosterone. Treasure Island, FL: StatPearls; 2021.

Bilińska B, Wiszniewska B, Kosiniak-Kamysz K, Kotula-Balak M, Gancarczyk M, Hejmej A, et al. Hormonal status of male reproductive system: Androgens and estrogens in the testis and epididymis. In vivo and in vitro approaches. Reprod Biol 2006;6 Suppl 1:43-58.

Wilczynski C, Agrawal LL. Testosterone effects on the prostate gland: Review of pathophysiology and considerations in prostate cancer. J Fam Med Dis Prev 2015;1:4.

Huggins C, Stevens RB, Hodges CV. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-3.

Chistiakov DA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Role of androgens in cardiovascular pathology. Vasc Health Risk Manage 2018;14:283.

Ng CF, Chiu PK, Yee CH, Lau BS, Leung SC, Teoh JY. Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: A prospective cohort study. Sci Rep 2020;10:1-9.

Dockery FM, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 2003;104:195-201.

Roe M. Assessment of Cardiovascular Risk with the Use of Androgen Deprivation Therapy for Prostate Cancer. Everyday 16; 2017.

Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome. Cancer 2008;112:2188-94.

Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 2007;9 Suppl 1:S3.

Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: From discovery to standard of care in castration resistant prostate cancer. Front Oncol 2019;9:801.

Mitka M. New basic care goals seek to rein in global rise in cardiovascular disease. JAMA 2012;308:1725-6.

Zareba P, Duivenvoorden W, Leong DP, Pinthus JH. Androgen deprivation therapy and cardiovascular disease: What is the linking mechanism? Ther Adv Urol 2016;8:118-29.

Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, et al. Androgen deprivation therapy for the treatment of prostate cancer: Consider both benefits and risks. Eur Urol 2009;55:62-75.

Perrone V, Esposti LD, Giacomini E, Veronesi C, Blini V, Oderda M. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: An Italian real-world analysis. Ther Clin Risk Manage 2020;16:393.

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-500.

Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-24.

Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009;27:3452.

Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, Type 2 diabetes, and cardiovascular disease: A review. Am J Clin Oncol 2012;35:504-9.

Garnick MB, Pratt CM, Campion M, Shipley J. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: Phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. J Clin Oncol 2004;22 Suppl 14:4578.

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: A meta-analysis. Eur Urol 2015;68:386-96.

Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Nihoyannopoulos P, Kemp M, et al. Anti‐androgens increase N‐terminal pro‐BNP levels in men with prostate cancer. Clin Endocrinol 2008;68:59-65.

Moreira RB, Debiasi M, Francini E, Nuzzo PV, De Velasco G, Maluf FC, et al. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials. Oncotarget 2017;8:84572.

Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: A review. Cancer 2008;113:1097-106.

Sun N, Xi Y, Jing S, Lu X. Morning blood pressure surge varies with age and gender in hypertensive individuals. Int J Cardiol 2009;135:272-3.

Sasaki R, Yamano S, Yamamoto Y, Minami S, Yamamoto J, Nakashima T, et al. Vascular remodeling of the carotid artery in patients with untreated essential hypertension increases with age. Hypertens Res 2002;25:373-9.

Ashman JJ, Rui P, Schappert SM. Age Differences in Visits to Office-based Physicians by Adults with Hypertension. United States: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2016.

Amery A, Wasir H, Bulpitt C, Conway J, Fagard R, Lijnen P, et al. Aging and the cardiovascular system. Acta Cardiol 1978;33:443-67.

Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Executive summary: Heart disease and stroke statistics 2011 update: A report from the American heart association. Circulation 2011;123:459-63.

Fathima M, Najeeb S, Fatima S, Khalid SM, Nikhat SR, Rao RC. A prospective observational study on risk factors and management of stroke at a tertiary care teaching hospital. Int J Pharm Pharm Sci 2018;10:24983.

Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 2018;16:e645-53.

Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39-46.

D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-5.

Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 2011;60:1244-50.

Liu R, Zhou J, Xia S, Li T. Androgen deprivation therapy and the risk of stroke in patients with prostate cancer: An updated systematic review and meta-analysis. Urol Int 2020;104:214-21.

Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, et al. Gonadotropin-releasing hormone agonists, orchiectomy, and risk of cardiovascular disease: Semi-ecologic, nationwide, population-based study. Eur Urol 2017;72:920-8.

Tivesten Å, Pinthus JH, Clarke N, Duivenvoorden W, Nilsson J. Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms. In: Urologic Oncology: Seminars and Original Investigations. Vol. 33. Amsterdam, Netherlands: Elsevier; 2015. p. 464-75.

Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American heart association, American cancer society and American urological association: Endorsed by the American society for radiation Oncology. Circulation 2010;121:833-40.

Schmidt B, Eapen RS, Cowan JE, Broering JM, Greene KL, Carroll PR, et al. Practice patterns of primary EBRT with and without ADT in prostate cancer treatment. Prost Cancer Prostat Dis 2019;22:117-24.

Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer. Cancer 2009;115:2388-99.

Tanaka G, Hirata Y, Goldenberg SL, Bruchovsky N, Aihara K. Mathematical modelling of prostate cancer growth and its application to hormone therapy. Philos Trans R Soc A Math Phys Eng Sci 2010;368:5029-44.

Carroll PH, Mohler JL. NCCN guidelines updates: Prostate cancer and prostate cancer early detection. J Natl Compr Cancer Netw 2018;16:620-3.

Virgo KS, Rumble RB, de Wit R, Mendelson DS, Smith TJ, Taplin ME, et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol 2021;39:1274-305.

Van Poppel H, Tombal B. Cardiovascular risk during hormonal treatment in patients with prostate cancer. Cancer Manage Res 2011;3:49.

Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, et al. Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. In: Urologic Oncology: Seminars and Original Investigations. Amsterdam, Netherlands: Elsevier; 2020.

Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, Choueiri TK, et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 2012;82:1411-6.